 | |
| Clinical data | |
|---|---|
| Other names | Desmethylapalutamide; Norapalutamide |
| Drug class | Nonsteroidal antiandrogen |
| Pharmacokinetic data | |
| Protein binding | 95%[1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C20H13F4N5O2S |
| Molar mass | 463.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-Desmethylapalutamide is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of apalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer.[2][1] It has similar activity to that of apalutamide and, with apalutamide therapy, circulates at similar concentrations to those of apalutamide at steady state.[1][failed verification] N-Desmethylapalutamide is formed from apalutamide in the liver by the cytochrome P450 enzymes CYP2C8 and CYP3A4.[1]
References
- ^ a b c d "ERLEADATM (apalutamide) tablets, for oral use" (PDF). Janssen Biotech, Inc. U.S. Food and Drug Administration.
- ^ Pérez-Ruixo C, Pérez-Blanco JS, Chien C, Yu M, Ouellet D, Pérez-Ruixo JJ, Ackaert O (February 2020). "Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects". Clinical Pharmacokinetics. 59 (2): 229–244. doi:10.1007/s40262-019-00808-7. PMID 31432469. S2CID 201065140.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 8 August 2022, at 01:30